|
| Index | - | P/E | - | EPS (ttm) | -1.39 | Insider Own | 11.70% | Shs Outstand | 35.33M | Perf Week | 4.60% |
| Market Cap | 56.69M | Forward P/E | - | EPS next Y | -1.67 | Insider Trans | 0.55% | Shs Float | 31.35M | Perf Month | 15.20% |
| Income | -49.10M | PEG | - | EPS next Q | -0.34 | Inst Own | 69.80% | Short Float / Ratio | 0.74% / 2.29 | Perf Quarter | -2.57% |
| Sales | - | P/S | - | EPS this Y | -98.00% | Inst Trans | -4.19% | Short Interest | 0.23M | Perf Half Y | -36.38% |
| Book/sh | 4.36 | P/B | 0.39 | EPS next Y | -33.80% | ROA | -27.40% | Target Price | 3.67 | Perf Year | -71.86% |
| Cash/sh | 4.63 | P/C | 0.37 | EPS next 5Y | 42.90% | ROE | -28.90% | 52W Range | 1.13 - 7.31 | Perf YTD | 3.33% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -76.68% | Beta | - |
| Dividend % | - | Quick Ratio | 27.10 | Sales past 5Y | - | Gross Margin | - | 52W Low | 50.88% | ATR | 0.15 |
| Employees | 40 | Current Ratio | 27.10 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 57.14 | Volatility | 7.09% 10.65% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 6.30% | Profit Margin | - | Rel Volume | 0.49 | Prev Close | 1.59 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 101.46K | Price | 1.71 |
| Recom | 1.70 | SMA20 | 5.64% | SMA50 | 14.88% | SMA200 | -20.53% | Volume | 49,439 | Change | 7.23% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite